EMERGENT BIOSOLUTIONS INC (EBS)       13.1  -0.37 (-2.75%)

13.1  -0.37 (-2.75%)

US29089Q1058 - Common Stock

Buy % Consensus

Analysts have set a mean price target of 31.11. This target is 137.48% above the current price.
EBS was analyzed by 11 analysts. The buy percentage consensus is at 71. So analysts seem to be have mildly positive about EBS.
In the previous month the buy percentage consensus was at a similar level.
EBS was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.

Price Target

Price Low Median Mean High 13.1023.2326.0131.1157.75 - 77.33% 98.55% 137.48% 340.84%

Up and Down Grades

Date Firm Action Rating
2022-11-10 Benchmark Downgrade Buy -> Hold
2022-11-09 Chardan Capital Maintains Buy
2022-09-12 Cowen & Co. Maintains Market Perform
2022-05-04 Wells Fargo Maintains Equal-Weight
2022-04-29 Chardan Capital Maintains Buy
2022-03-10 Wells Fargo Maintains Equal-Weight
2021-11-10 Chardan Capital Maintains Buy
2021-11-08 Benchmark Downgrade Buy -> Hold
2021-05-05 Argus Research Downgrade Buy -> Hold
2021-04-30 Chardan Capital Maintains Buy
2021-04-07 Benchmark Initiate Buy
2021-02-24 Chardan Capital Upgrade Neutral -> Buy
2021-02-19 Chardan Capital Downgrade Buy -> Neutral

Analyst Ratings Stock Screener Links

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA